CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 111 enrolled
Drug / intervention
AZD6094drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02127710
NCT02127710Phase 2Completed
CompareCT.gov

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

AstraZeneca·interventional·Posted May 1, 2014·Updated Apr 19, 2021

In Brief

A Phase 2 clinical trial evaluating AZD6094 for Papillary Renal Cell Cancer. Completed, enrolled 111 participants across 23 sites in 4 countries.

Detailed Summary

This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapillary Renal Cell Cancer
CountriesCanada, Spain, United Kingdom, United States
CollaboratorsSCRI Development Innovations, LLC

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 1, 2014
Enrollment StartApr 30, 2014
Primary CompletionApr 14, 2016
Study CompletionApr 20, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.2 years ago

Interventions

AZD6094drug

AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.